secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2024-12-18T23:59:59+00:00
Accession:  0001628280-24-051729
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Chairman Dr. Given to retire; Sarepta CEO Ingram expected to join board
--------------------------------------------------------------------------------

- Dr. Douglass Given retires from Board effective Dec 31, 2024, after 14 years as Chairman.
- Douglas S. Ingram, President and CEO of Sarepta Therapeutics, expected to join Board in Q1 2025.
- Ingram's appointment aligns with closing of Arrowhead-Sarepta Exclusive License and Collaboration Agreement (Nov 25, 2024).
- Company expresses gratitude for Dr. Given's service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828024051729/0001628280-24-051729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828024051729/arwr-20241211.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-051729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer